Bozkurt, OktayKaraca, HalitHacibekiroglu, IlhanKaplan, Muhammed AliDuzkopru, YakupUysal, MukreminBerk, Veli2024-06-122024-06-1220161120-009X1973-9478https://doi.org/10.1179/1973947815Y.0000000039https://hdl.handle.net/20.500.14551/21732Background: The main goal of this study was to examine whether the occurrence of hypothyroidism during sunitinib therapy in patients with metastatic renal cell carcinoma (mRCC) is associated with a better outcome. Methods: The study enrolled 81 patients with pathologically proven mRCC who were treated with sunitinib between March 2008 and June 2013. Thyroid function evaluation comprised (free-thyroxine) FT4 and thyroid-stimulating hormone (TSH) before treatment and at day 1 of each 6-week cycle. Survival analysis was performed using the Kaplan-Meier method, and the differences among the groups were determined using the log-rank test. Results: Hypothyroidism occurred in 30 (37%) of 81 patients within a median 3 months (range 1-18) of treatment initiation. There was a statistically significant correlation between the occurrence of hypothyroidism during treatment and the rate of objective remission (ORR) (hypothyroid patients vs euthyroid patients: 46.7 vs 13.7%, respectively; P = 0.001). Median progression-free survival (PFS) was 10 (95% CI 6.13-13.8) months in the euthyroid patients, and 17 (95% CI 9.33-24.6) months in the hypothyroid patients (P = 0.001). The median overall survival (OS) was 39 (95% CI 25.4-52.5) months in the hypothyroid patients and 20 (95% CI 14.7-25.2) months in the euthyroid patients (P = 0.019). Conclusions: The occurrence of hypothyroidism during treatment in patients was significantly associated with longer PFS, OS and better ORR in the current study.en10.1179/1973947815Y.0000000039info:eu-repo/semantics/closedAccessHypothyroidismSunitinibPrognosisMetastatic Renal Cell CancerThyroid-HormoneCancer-PatientsKinaseArticle283230234Q4WOS:0003802837000152-s2.0-8497870168225948423Q3